View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
March 28, 2018

A step towards earlier detection of Parkinson’s disease

Alpha-synuclein imaging agents to help detect Parkinson’s disease will progress to human studies later this year.

By GBI Research

Alpha-synuclein imaging agents to help detect Parkinson’s disease will progress to human studies later this year.

A positron emission tomography (PET) tracer that is able to detect and track the disease will lead to earlier and more accurate diagnosis, and will transform research and patient care.

A widespread issue

Parkinson’s disease is a neurodegenerative disorder that affects the motor system, and is characterized by tremors, slow movement and muscle stiffness.

It causes progressive disability, to the extent that sufferers lose their independence.

Incidence increases with age, and it is estimated that 7–10 million people are living with the disease worldwide.

Approximately 60,000 Americans are diagnosed each year, but there are also thousands of cases that go undetected, partly because elderly patients assume their Parkinson’s disease symptoms are the result of normal aging, and don’t seek medical assistance.

There is currently no treatment that can slow or halt disease progression.

A new method of diagnosis

AC Immune SA, a Swiss-based biopharmaceutical company, recently announced a significant step towards the first potential PET tracer for Parkinson’s disease, as it plans to initiate a first-in-human study during the second half of 2018.

The new compound is highly selective for alpha-synuclein aggregates – an established target for Parkinson’s disease and other diseases with alpha-synuclein pathologies.

This technology will enable the disease to be detected earlier and more accurately, which is critical for disease management, and will also allow for the monitoring of the efficacy of therapeutics reducing alpha-synuclein aggregates in clinical trials.

The program involved collaborated with Biogen, and was supported by the Michael J Fox Foundation for Parkinson’s Research.

The companies will continue to develop the alpha-synuclein PET tracer, with the aim of enabling clinical development of new disease-modifying therapies.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU